GlassScriptPhysician profile
Michael C Kim
NPI 1710908140
$4,243.20
in general payments reported to CMS, 2019-2025
18 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.47 · 2020: $30.48 · 2021: $81.76 · 2022: $135 · 2023: $459 · 2024: $1,927 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,977.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $829.63 | 2022-2025 | |
| Janssen Biotech, INC. | $624.40 | 2022-2025 | Tremfya, Simponi, Remicade |
| Regeneron Healthcare Solutions, INC. | $533.80 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $464.68 | 2024-2025 | Bimzelx |
| Pfizer INC. | $464.30 | 2019-2025 | |
| Amgen INC. | $347.61 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $234.51 | 2024-2025 | Sotyktu |
| Incyte Corporation | $199.46 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $175.92 | 2024-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $111.85 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $79.94 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $42.07 | 2024 | Zoryve |
| Lilly USA, LLC | $30.44 | 2025 | Ebglyss, Taltz |
| Smith+Nephew, INC. | $30.09 | 2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.50 | 2024 | Cyltezo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $24.93 | 2025 | Vtama |
| Gilead Sciences, INC. | $21.07 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.